NCT00138086View on ClinicalTrials.gov

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

March 31, 2009

Conditions
B-Cell Lymphoma
Interventions
DRUG

Zevalin plus BEAM

Trial Locations (9)

59000

Hématologie CHU de Lille, Lille

69495

Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite

75005

Institut Curie, Paris

75010

Hôpital Saint Louis, Paris

76038

Centre Henri Becquerel, Rouen

94010

Hôpital Henri Mondor, Créteil

Unknown

Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne

Institut Gustave Roussy, Villejuif

Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne

All Listed Sponsors
lead

Lymphoma Study Association

OTHER

NCT00138086 - Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma | Biotech Hunter | Biotech Hunter